Dr. Christopher S. Strouse, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Wisconsin School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 311
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Wisconsin School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IA license MD-43488 -
Hospitalist Physician
IA license 43488 -
Internal Medicine Physician
IA license MD-43488
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Southeast Iowa Regional Medical Center West Burlington, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 311
- Services billed
- 1,089
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 301 | 201 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 263 | 40 |
| Established patient office or other outpatient visit, 40-54 minutes | 106 | 76 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 70 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 26 | 26 |
| Hospital discharge day management, more than 30 minutes | 26 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 22 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Iowa City, IA | 96 |
| Eliquis (apixaban) Other prescribers in Iowa City, IA | 45 |
| Prochlorperazine Maleate Other prescribers in Iowa City, IA | 39 |
| Ondansetron Hcl Other prescribers in Iowa City, IA | 35 |
| Dexamethasone Other prescribers in Iowa City, IA | 29 |
| Omeprazole Other prescribers in Iowa City, IA | 20 |
| Lenalidomide | 18 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Iowa City, IA | 17 |
| Gabapentin Other prescribers in Iowa City, IA | 16 |
| Revlimid (lenalidomide) | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $2,880 in total to this clinician.
| Pfizer Inc. | $2,880 |
|---|
| Consulting Fee | $2,880 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Oct 30, 2025 | Consulting Fee ELREXFIO · ONCOLOGY | $2,880 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 3 companies. The companies reported $1,199,042 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combinat…
Janssen Research & Development, LLC - A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against BCMA in Subjects with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Celgene Corporation - A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, …
Janssen Research & Development, LLC - A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in Combinat…
Janssen Research & Development, LLC - Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, …
Janssen Research & Development, LLC - A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
E.r. Squibb & Sons, L.l.c. - A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.